Radius Health (RDUS) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update
November 2, 2017 4:02 PM EDTFirst full quarter of TYMLOS sales shows accelerating market share & stabilization of the anabolic market
Plan access at approximately 200 million lives 87% commercial and 35% Medicare
Male Osteo Trial: FDA agreÂement on the design of a clinical trial in men
FDA Fast Track Designation for elacestrant (RAD1901)
First patient enrolled in Phase 1 study of RAD140
Strengthened balance sheet with $305 million convertible debt offering
WALTHAM, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the... More
